Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Anatomic Stage II Breast Cancer AJCC v8|Anatomic Stage III Breast Cancer AJCC v8|HER2-Negative Breast Carcinoma|Hormone Receptor-Positive Breast Carcinoma
Interventions: PROCEDURE: Biospecimen Collection|DRUG: Cyclophosphamide|DRUG: Doxorubicin|BIOLOGICAL: Durvalumab|OTHER: Genetic Testing|PROCEDURE: Mammography|DRUG: Paclitaxel|OTHER: Quality-of-Life Assessment
Sponsor: National Cancer Institute (NCI)